ERBB2 and breast cancer: HER2-BC has limited treatment options because of the lack of corresponding receptor expression.[31] High recurrence risk, poor prognosis and high metastasis rate pose challenges to the physical and mental health, economic burden, OS and quality of life of BC patients.[32]